US Bancorp’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-700
| Closed | -$1.05K | – | 4185 |
|
|
2023
Q1 | $1.05K | Hold |
700
| – | – | ﹤0.01% | 3860 |
|
|
2022
Q4 | $699 | Hold |
700
| – | – | ﹤0.01% | 3966 |
|
|
2022
Q3 | $1K | Hold |
700
| – | – | ﹤0.01% | 4044 |
|
|
2022
Q2 | $2K | Hold |
700
| – | – | ﹤0.01% | 3906 |
|
|
2022
Q1 | $2K | Sell |
700
-150
| -18% | -$472 | ﹤0.01% | 3890 |
|
|
2021
Q4 | $4K | Sell |
850
-3,656
| -81% | -$22.9K | ﹤0.01% | 3757 |
|
|
2021
Q3 | $38K | Sell |
4,506
-18,368
| -80% | -$260K | ﹤0.01% | 2788 |
|
|
2021
Q2 | $375K | Buy |
22,874
+150
| +0.7% | +$3.03K | ﹤0.01% | 1692 |
|
|
2021
Q1 | $502K | Buy |
22,724
+1,309
| +6% | +$35.7K | ﹤0.01% | 1486 |
|
|
2020
Q4 | $663K | Buy |
21,415
+20,715
| +2,959% | +$524K | ﹤0.01% | 1293 |
|
|
2020
Q3 | $14K | Hold |
700
| – | – | ﹤0.01% | 2964 |
|
|
2020
Q2 | $11K | Hold |
700
| – | – | ﹤0.01% | 3087 |
|
|
2020
Q1 | $5K | Buy |
700
+300
| +75% | +$3.67K | ﹤0.01% | 3288 |
|
|
2019
Q4 | $6K | Hold |
400
| – | – | ﹤0.01% | 3253 |
|
|
2019
Q3 | $6K | Buy |
+400
| New | +$6.23K | ﹤0.01% | 3217 |
|
US Bancorp's TCRR Position: Q2 2023 in Review
US Bancorp sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 700 shares — an estimated $1.05K sold.
US Bancorp first reported a position in TCRR in Q3 2019 and held it in 15 quarters. The position peaked at $663K in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- US Bancorp reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- US Bancorp sold 700 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1.05K.
- US Bancorp first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- US Bancorp's TCR2 Therapeutics Inc. Common Stock position peaked at $663K in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.